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PThe Effect of Pioglitazone on Recurrent
Myocardial Infarction in 2,445 Patients With
Type 2 Diabetes and Previous Myocardial Infarction
Results From the PROactive (PROactive 05) Study
Erland Erdmann, MD, FESC, FACC,* John A. Dormandy, FRCS, DSC,† Bernard Charbonnel, MD,‡
Massimo Massi-Benedetti, MD,§ Ian K. Moules, BSC (HONS), Allan M. Skene, PHD,¶
on behalf of the PROactive Investigators
Köln, Germany; London and Nottingham, United Kingdom; Nantes, France; and Perugia, Italy
Objectives This analysis from the PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events) study as-
sesses the effects of pioglitazone on mortality and macrovascular morbidity in patients with type 2 diabetes and
a previous myocardial infarction (MI).
Background People with type 2 diabetes have an increased incidence of MI compared with the general population. Those
with diabetes and MI have a worse prognosis than nondiabetic patients with cardiovascular disease.
Methods The PROactive study was a prospective, multicenter, double-blind, placebo-controlled trial of 5,238 patients with
type 2 diabetes and macrovascular disease. Patients were randomized to either pioglitazone or placebo in addi-
tion to their other glucose-lowering and cardiovascular medication. Treatment of diabetes, dyslipidemia, and
hypertension was encouraged according to the International Diabetes Federation guidelines. Patients were followed
for a mean of 2.85 years. The primary end point was the time to first occurrence of macrovascular events or death.
Of the total cohort, the subgroup of patients who had a previous MI (n 2,445 [46.7%]; n  1,230 in the pioglita-
zone group and n  1,215 in the placebo group) was evaluated using prespecified and post-hoc analyses.
Results Pioglitazone had a statistically significant beneficial effect on the prespecified end point of fatal and nonfatal MI
(28% risk reduction [RR]; p  0.045) and acute coronary syndrome (ACS) (37% RR; p  0.035). There was a
19% RR in the cardiac composite end point of nonfatal MI (excluding silent MI), coronary revascularization, ACS,
and cardiac death (p  0.033). The difference in the primary end point defined in the main PROactive study did
not reach significance in the MI population (12% RR; p  0.135). The rates of heart failure requiring hospitaliza-
tion were 7.5% (92 of 1,230) with pioglitazone and 5.2% (63 of 1,215) with placebo. Fatal heart failure rates
were similar (1.4% [17 of the 92] with pioglitazone versus 0.9% [11 of the 63] with placebo).
Conclusions In high-risk patients with type 2 diabetes and previous MI, pioglitazone significantly reduced the occurrence of
fatal and nonfatal MI and ACS. (PROspective pioglitAzone Clinical Trial In macroVascular Events; http://www.
clinicaltrials.gov/ct/show/NCT00174993?order  1; ISRCTN NCT00174993). (J Am Coll Cardiol 2007;49:
1772–80) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.12.048n
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May 1, 2007:1772–80 Pioglitazone’s Effects in T2DM and Previous MIithout diabetes (4 –7). It is therefore particularly impor-
ant to improve the unfavorable outcome of people with
iabetes and MI.
A subanalysis from the UKPDS (United Kingdom Prospec-
ive Diabetes Study) looked at differences in risk factors
etween those with diabetes and fatal versus nonfatal MI and
howed that the risk of MI being fatal in type 2 diabetes
ncreased with increasing hemoglobin (Hb)A1c (8). This is
upported by data from DECODE (Diabetes Epidemiology:
ollaborative Analysis of Diagnostic Criteria in Europe) and
ther studies (9,10). The cardiovascular risk in patients with
ype 2 diabetes who have had at least 1 MI is increased further
f they have coexisting dyslipidemia, arterial hypertension, or
oronary artery disease (11). Current guidelines recommend
ggressive management of these cardiovascular risk factors,
ncluding hyperglycemia (using glucose-lowering agents), dys-
ipidemia (using statins), hypertension (using angiotensin-
onverting enzyme [ACE] inhibitors or angiotensin II receptor
locker therapy), and lifestyle factors (12–15). However, there
re few outcome studies that look at the effect of glucose-
owering agents on end points related to macrovascular disease.
Pioglitazone, a thiazolidinedione, is an established oral
herapy for the management of type 2 diabetes. In addition
o its effects on fasting and postprandial hyperglycemia,
ioglitazone also increases insulin sensitivity and is known
o have positive effects on high-density lipoprotein (HDL)
holesterol, triglycerides, and low-density lipoprotein
LDL) particle size (16–21). There is some evidence to
uggest that pioglitazone may also have other beneficial
ntiatherogenic properties, such as regulating the levels of
ediators involved in inflammation and endothelial dys-
unction (22). Indeed, data now suggest that combining
ioglitazone with other medication for cardiovascular risk
actors may have complementary effects in patients with
ype 2 diabetes (23–25). Therefore, it was anticipated that
ioglitazone in addition to current therapy would reduce the
ecurrence of cardiovascular events in a population with
iabetes at high risk of macrovascular events.
The PROactive (PROspective pioglitAzone Clinical
rial In macroVascular Events) study is one of a series of
tudies evaluating the effects of pioglitazone on the progres-
ion of atherosclerosis in patients with type 2 diabetes. It
as the first large prospective study to look at the reduction
n total mortality and macrovascular morbidity using thia-
olidinedione. The primary composite end point included
oth disease (e.g., death, MI, acute coronary syndrome
ACS], and stroke) and procedure-related end points (e.g.,
oronary and leg revascularization). Data from the total
tudy population showed that there was a 10% risk reduc-
ion (RR) in the primary composite end point of macrovas-
ular events in the pioglitazone group compared with the
lacebo group. This did not reach statistical significance
p  0.095) (26). However, there was a statistically signif-
cant 16% RR (p 0.027) in the main secondary end point.
his included only disease-related end points—the compos-te of all-cause mortality, nonfatal MI, and nonfatal stroke r26). An analysis of the patients
ntering the study with a previ-
us MI was prespecified in the
tatistical Analysis Plan, as these
atients tend to have the worst
rognosis. We have further ex-
lored the basis of the findings
sing post-hoc exploratory anal-
ses. Although this investigation
ncludes both prespecified and
ost-hoc analyses, it involves one
f the largest groups of patients
ith type 2 diabetes and previous
I to be examined in a prospec-
ive randomized study.
ethods
atients. PROactive was a ran-
omized, double-blind, placebo-
ontrolled outcome study in pa-
ients with type 2 diabetes (ages 35 to 75 years) who were at
ncreased macrovascular risk. The study randomized 5,238
atients from 19 European countries and observed them for
n average of 34.5 months. The study protocol, inclusion
nd exclusion criteria, and analytical methods have been
escribed previously (26,27).
reatments. Patients were randomized to receive pioglita-
one (increased stepwise from 15 to 30 to 45 mg within the
rst 2 months, depending on tolerability) or matching
lacebo, in addition to their existing medication for man-
gement of hyperglycemia, dyslipidemia, and hypertension.
aseline Characteristics and Previousacrovascular Mo bidity in Pati nts With Type 2i betes and Previous Myocardial Infarction
Table 1
Baseline Characteristics and Previous
Macrovascular Morbidity in Patients With Type 2
Diabetes and Previous Myocardial Infarction
Pioglitazone
(n  1,230)
Placebo
(n  1,215)
Patient characteristics
Male, n (%) 909 (73.9%) 895 (73.7%)
Caucasian, n (%) 1,211 (98.5%) 1,198 (98.6%)
Age (yrs), mean (SD) 61.8 (7.8) 61.8 (7.6)
Time since diagnosis of diabetes (yrs),
median (IQR)
8 (4, 13) 8 (4, 13)
Body mass index (kg/m2), mean (SD) 30.9 (4.6) 31.2 (4.7)
History of hypertension, n (%) 865 (70.3%) 894 (73.6%)
Smoking
Current, n (%) 146 (11.9%) 154 (12.7%)
Past, n (%) 636 (51.7%) 595 (49.0%)
Microvascular disease,* n (%) 507 (41.2%) 465 (38.3%)
Other macrovascular disease criteria
Previous stroke, n (%) 91 (7.4%) 86 (7.1%)
Previous PCI/CABG, n (%) 528 (42.9%) 495 (40.7%)
Previous ACS, n (%) 158 (12.8%) 169 (13.9%)
Symptomatic peripheral arterial
obstructive disease, n (%)
99 (8.0%) 106 (8.7%)
Retinopathy, nephropathy, neuropathy.
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ACS  acute coronary
syndrome
CABG  coronary artery
bypass graft
ECG  electrocardiogram
HDL  high-density
lipoprotein
HF  heart failure
IDF  International
Diabetes Federation
LDL  low-density
lipoprotein
MI  myocardial infarction
PCI  percutaneous
coronary interventionACS  acute coronary syndrome; CABG  coronary a
ange; PCI  percutaneous coronary intervention.rtery bypass graft; IQR  interquartile
I
t
F
t
q
a
2
a
e
E
m
fi
m
s
b
t
a
e
M
w
t
i
c
m
i
w
f
n
o
d
a
m
d
c
s
d
D
f
P
s

o
BD
H ipoprote
1774 Erdmann et al. JACC Vol. 49, No. 17, 2007
Pioglitazone’s Effects in T2DM and Previous MI May 1, 2007:1772–80nvestigators were encouraged to treat these conditions
hroughout the trial according to the International Diabetes
ederation (IDF) Europe Guidelines (1999) (28).
The analysis presented here investigates the effects of
reatment with pioglitazone versus placebo in patients who
ualified for entry into the PROactive study on the basis of
previous MI 6 months or more before randomization (n
,445). The 6-month restriction was applied to ensure that
ll patients were in a stable myocardial condition before
ntry into the study.
nd points. The primary end point, as described by Dor-
andy et al. (26), was the time from randomization to the
rst occurrence of any of the following events: all-cause
ortality, nonfatal MI (including silent infarction), nonfatal
troke, ACS, cardiac intervention (including coronary artery
ypass graft [CABG], or percutaneous coronary interven-
ion [PCI]), leg revascularization, and amputation above the
nkle. The main secondary end point was time to the first
vent of death from any cause, nonfatal MI (excluding silent
I), or nonfatal stroke. This secondary “hard” end point
as analyzed because these disease-related components are
he most robust and objective. Other secondary end points
aseline and Change From Baseline Laboratory and Blood Pressureta P tients With Type 2 Diabetes and Previous My cardial Inf
Table 2 Baseline and Change From Baseline Laboratory and BlData in Patients With Type 2 Diabetes and Previous M
Level at Baseline
Pioglitazone Plac
%
HbA1c, median (IQR) 7.9 (7.1, 8.9) 7.9 (7.
mmol/l
Triglycerides, median (IQR) 1.8 (1.3, 2.6) 1.8 (1.
HDL cholesterol, median (IQR) 1.1 (0.9, 1.3) 1.1 (0.
LDL cholesterol, median (IQR) 2.8 (2.3, 3.5) 2.8 (2.
Ratio
LDL/HDL, median (IQR) 2.6 (2.1, 3.2) 2.5 (2.
mm Hg
Blood pressure: systolic, median (IQR) 140 (130, 150)
Blood pressure: diastolic, median (IQR) 80 (73, 85)
b  hemoglobin; HDL  high-density lipoprotein; IQR  interquartile range; LDL  low-density l
Glucose-Lowering Therapies in Patients WithType 2 Diabetes and Previous Myocardial Infarc
Table 3 Glucose-Lowering Therapies in PatieType 2 Diabetes and Previous Myoc
Pioglitaz
(n  1,2
Metformin only, n (%) 128 (10
Sulfonylureas only, n (%) 260 (21
Metformin  sulfonylureas, n (%) 306 (24
Insulin  metformin, n (%) 216 (17
Insulin  sulfonylureas, n (%) 91 (7.4
Insulin  metformin  sulfonylureas, n (%) 41 (3.3
Other combination, n (%) 134 (10
Diet only, n (%) 50 (4.1
Any metformin, n (%) 749 (60
Any sulfonylurea, n (%) 760 (61Any insulin, n (%) 396 (32.2%)ncluded time to individual components of the primary
omposite and time to cardiovascular death. These are the
ain study end points (26).
The statistical analysis plan, finalized before the unblind-
ng of the study, prioritized this previous-MI subgroup (as
ell as the previous-stroke subgroup) for analysis of the
ollowing prespecified composite end points: 1) fatal or
onfatal MI (excluding silent MI), 2) cardiovascular death
r nonfatal MI (excluding silent MI), and 3) cardiovascular
eath, nonfatal MI (excluding silent MI), or stroke. In this
rticle, we describe these prespecified end points. Further-
ore, we were interested in the outcome of ACS, which was
efined by objective clinical criteria, and a further composite
ardiac end point of nonfatal MI (excluding and including
ilent MI), coronary revascularization, ACS, or cardiac
eath.
efinitions. The definition for nonfatal MI was survival
or 24 h from onset of symptoms and, in the absence of
CI or CABG, at least 2 of the following: 1) symptoms
uggestive of MI (ischemic chest pain or discomfort) lasting
30 min, 2) electrocardiographic (ECG) evidence of MI,
r 3) elevation of cardiac serum markers, or following PCI
on
ressure
rdial Infarction
Change From Baseline
Pioglitazone Placebo p Value
Absolute change
0.8 (1.6,0.1) 0.4 (1.1, 0.3) 0.0001
% change
11.1 (34.7, 17.9) 1.3 (25.5, 35.2) 0.0001
18.8 (6.6, 33.3) 10.0 (1.9, 21.6) 0.0001
7.8 (11.6, 27.7) 4.5 (14.2, 24.1) 0.0268
% change
9.1 (27.1, 9.3) 4.4 (22.5, 16.1) 0.0001
Absolute change
2 (15, 10) 0 (15, 10) 0.2822
2 (10, 4) 2 (10, 3) 0.5215
in.
With
l Infarction
aseline At Final Visit
Placebo
(n  1,215)
Pioglitazone
(n  1,140)
Placebo
(n  1,114)
119 (9.8%) 127 (11.1%) 109 (9.8%)
256 (21.1%) 209 (18.3%) 138 (12.4%)
280 (23.0%) 240 (21.1%) 251 (22.5%)
228 (18.8%) 182 (16.0%) 232 (20.8%)
102 (8.4%) 62 (5.4%) 79 (7.1%)
47 (3.9%) 43 (3.8%) 54 (4.8%)
128 (10.5%) 108 (9.5%) 93 (8.3%)
52 (4.3%) 83 (7.3%) 41 (3.7%)
716 (58.9%) 639 (56.1%) 681 (61.1%)
743 (61.2%) 604 (53.0%) 568 (51.0%)arcti
ood P
yoca
ebo
1, 9.0)
3, 2.6)
9, 1.3)
2, 3.4)
0, 3.3)tion
nts
ardia
At B
one
30)
.4%)
.1%)
.9%)
.6%)
%)
%)
.9%)
%)
.9%)
.8%)419 (34.5%) 410 (36.0%) 517 (46.4%)
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May 1, 2007:1772–80 Pioglitazone’s Effects in T2DM and Previous MIr CABG if there was ECG evidence of MI. Silent MI was
efined as new Q waves in 2 contiguous leads or R-wave
eduction in the precordial leads without a change in axis
eviation. All potential end point events were adjudicated
entrally by an independent committee of clinical experts.
ardiovascular deaths were all deaths excluding those with
proven noncardiovascular cause. Cardiac death was de-
ned as death attributable to MI or other cardiac diseases.
rocedures. Patients were seen at months 1 and 2, then
very 2 months for the first year, and every 3 months until
he last visit. All patients were followed until the end of the
tudy. Vital signs and body weight were measured at each
isit. Standard ECGs were obtained at baseline, at yearly
ntervals, and at the last visit. Blood samples for various
Concomitant Cardiovascular Medication in PatieWith Type 2 Di betes and Previous Myocardi l
Table 4 Concomitant Cardiovascular MedicaWith Type 2 Diabetes and Previous
At Ba
Pioglitazone
Beta-blockers, n (%) 806 (65.5%)
ACE inhibitors, n (%) 783 (63.7%)
Angiotensin II antagonists, n (%) 74 (6.0%)
Calcium channel blockers, n (%) 372 (30.2%)
Nitrates, n (%) 606 (49.3%)
Thiazide diuretics, n (%) 163 (13.3%)
Loop diuretics, n (%) 207 (16.8%)
Antiplatelet medication, n (%) 1,118 (90.9%)
Aspirin, n (%) 988 (80.3%)
Statins, n (%) 614 (49.9%)
Fibrates, n (%) 127 (10.3%)
ACE  angiotensin-converting enzyme.
ffects of Add-On Pioglitazone Therapy Versus Placebo onardiac-Related Events in Patients With Type 2 Diabetes and Previ
Table 5 Effects of Add-On Pioglitazone Therapy Versus PlaceboCardiac-Related Events in Patients With Type 2 Diabet
Event
Piogl
(n 
End points prespecified for the previous-MI subgroup
Fatal/nonfatal MI (excluding silent MI) 65 (
Cardiovascular death or nonfatal MI (excluding silent MI) 115 (
Cardiovascular death, nonfatal MI (excluding silent MI), or stroke 137 (
Main PROactive end points
Primary end point 263 (
Main secondary end point† 148 (
Individual end points from the primary end point
All-cause mortality 82 (
Cardiac death‡ 51 (
Nonfatal MI (including silent MI) 72 (
ACS 35 (
Coronary revascularization§ 99 (
Fatal/nonfatal stroke 35 (
Other composite end points
Composite end point of all cardiac events, excluding silent MI 180 (
Composite end point of all cardiac events, including silent MI 192 (
Pioglitazone versus placebo from a Cox proportional hazards model. †This was the main secon
onfatal stroke (26). ‡Cardiac death was defined as death classified as MI and “other cardiac”
Percutaneous coronary intervention and coronary artery bypass graft. Nonfatal MI, coronary revascular
CI  confidence interval; Est  estimated value.nalyses were taken at baseline and every 6 months. Details
f assays and specific methodology have been described
reviously (26).
tatistical analysis. Statistical methods and power calcu-
ations have been reported previously (26,27). Time-to-
vent analyses were carried out by fitting proportional
azards survival models with treatment as the only
ovariate and previous testing of the validity of the
ssumption of proportional hazards. Multivariate models
ere used to investigate the effect of treatment after
djustment for baseline factors identified as prognostic of
utcome. Variable selection was carried out using a
tepwise selection algorithm and a significance level of
.05. The study is registered as an International Stan-
tion
in Patients
cardial Infarction
At Final Visit
Placebo Pioglitazone Placebo
791 (65.1%) 778 (68.2%) 784 (70.4%)
804 (66.2%) 740 (64.9%) 769 (69.0%)
78 (6.4%) 107 (9.4%) 115 (10.3%)
402 (33.1%) 367 (32.2%) 407 (36.5%)
640 (52.7%) 517 (45.4%) 496 (44.5%)
174 (14.3%) 185 (16.2%) 214 (19.2%)
198 (16.3%) 282 (24.7%) 225 (20.2%)
065 (87.7%) 1,044 (91.6%) 1,016 (91.2%)
947 (77.9%) 915 (80.3%) 862 (77.4%)
639 (52.6%) 704 (61.8%) 707 (63.5%)
131 (10.8%) 91 (8.0%) 105 (9.4%)
I
d Previous MI
Hazard Ratio*
)
Placebo
(n  1,215) Est 95% CI p Value
88 (7.2%) 0.72 (0.52–0.99) 0.0453
132 (10.9%) 0.85 (0.66–1.09) 0.2013
) 158 (13.0%) 0.85 (0.67–1.06) 0.1493
) 292 (24.0%) 0.88 (0.75–1.04) 0.1351
) 178 (14.7%) 0.81 (0.65–1.01) 0.0585
94 (7.7%) 0.85 (0.63–1.15) 0.2873
60 (4.9%) 0.83 (0.57–1.20) 0.3231
85 (7.0%) 0.83 (0.60–1.13) 0.2333
54 (4.4%) 0.63 (0.41–0.97) 0.0346
121 (10.0%) 0.80 (0.61–1.04) 0.1000
36 (3.0%) 0.95 (0.60–1.52) 0.8380
) 217 (17.9%) 0.81 (0.66–0.98) 0.0336
) 224 (18.4%) 0.83 (0.69–1.01) 0.0651
d point in the main study—death, nonfatal myocardial infarction (MI) (excluding silent MI), and
eath associated with cardiac disease adjudicated by the independent adjudication committee).ntsI farc
tion
Myo
seline
1,ous M
on
es an
itazone
1,230
5.3%)
9.3%)
11.1%
21.4%
12.0%
6.7%)
4.1%)
5.9%)
2.8%)
8.0%)
2.8%)
14.6%
15.6%
dary en
(any dization, acute coronary syndrome (ACS), or cardiac death.
d
N
R
B
h
p
T
d
b
t
(
m
d
a
l
c
w
s
t
4
c
(
3
d
E
t
t
s
T
t
(
0
[
c
c
c
m
s
p
e
p
i
D
p
g
t
r
B
1776 Erdmann et al. JACC Vol. 49, No. 17, 2007
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CT00174993.
esults
aseline data. Baseline data of the total study population
ave been published previously (26). Baseline data of the
atients with type 2 diabetes and previous MI are given in
ables 1 and 2. Patient characteristics, baseline laboratory
ata, and previous macrovascular morbidities were well
alanced between the patients in the pioglitazone group and
hose in the placebo group. A high proportion of patients
more than two-thirds) in both groups had other evidence of
acrovascular disease (stroke, peripheral arterial obstructive
isease, PCI/CABG, or ACS).
There were also no differences between the pioglitazone
nd placebo groups with respect to baseline blood glucose-
owering treatments and concomitant cardiovascular medi-
ation (Tables 3 and 4). Approximately 90% of patients
ere receiving antiplatelet therapy; 51% were receiving
tatins at entry, and 63% were receiving statins at the end of
he study (Table 4). The final mean dose of pioglitazone was
3.9 mg/day in the 953 patients with previous MI who
ompleted the study on medication. Eighteen patients
1.9%) were receiving 15 mg/day, 34 (3.6%) were receiving
0 mg/day, and 901 (94.5%) were receiving the maximum
Figure 1 Time to Fatal/Nonfatal MI (Excluding Silent MI)
Kaplan-Meier curve of the time to fatal/nonfatal myocardial infarction (MI) (excludi
The solid line represents the pioglitazone group; the dashed line represents the pose of 45 mg/day. tffect of pioglitazone versus placebo. Table 5 describes
he effect of pioglitazone on the 3 end points prespecified for
he previous-MI subgroup, the primary end point, the main
econdary end point, and other cardiac-related end points.
here was a significant beneficial effect of pioglitazone on
he end points of fatal/nonfatal MI, excluding silent MI
RR  28%; p  0.045) (Fig. 1), ACS (RR  37%; p 
.035) and the composite cardiac end point (nonfatal MI
excluding silent MI], coronary revascularization, ACS, or
ardiac death; RR  19%; p  0.034) (Fig. 2).
There were no significant differences in the end point of
ardiovascular death or nonfatal MI, the end point of
ardiovascular death, nonfatal MI, or stroke, the primary or
ain secondary end points defined in the main PROactive
tudy, and the individual end points of the primary com-
osite; however, there was a consistently lower number of
vents in the pioglitazone-treated patients for all of the end
oints (Table 5). The number of silent MIs was similar: 14
n the pioglitazone group and 11 in the placebo group.
eaths from any cause occurred in 82 patients (6.7%) in the
ioglitazone group and 94 patients (7.7%) in the placebo
roup (RR  15%; p  0.287).
We performed multivariate analyses including other fac-
ors that could affect the likelihood of having either a
ecurrent MI or an event from the cardiac composite.
aseline characteristics that were significant risk factors for
nt MI).
group. CI  confidence interval; HR  hazard ratio.ng sile
lacebootal MI included elevated LDL cholesterol, insulin use,
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May 1, 2007:1772–80 Pioglitazone’s Effects in T2DM and Previous MInd increased age. In contrast, prior revascularization re-
uced the risk of a MI. We found that pioglitazone was still
ssociated with a hazard ratio (HR) of 0.72 after adjusting
or these significant risk factors (Table 6). The baseline
actors that had a major impact on the cardiac composite
ere elevated LDL cholesterol, long duration of diabetes
10 vs. 5 years), ACE inhibitor use, and high triglycer-
de levels (Table 6). Similar to the total MI end point,
revious revascularization reduced the risk for the cardiac
omposite (Table 6).
Changes from baseline to final visit for laboratory param-
ters are shown in Table 2. Median HbA1c decreased in the
ioglitazone group to a greater extent than in the placebo
roup. Median HDL cholesterol increased (8.8%) and
edian triglycerides decreased (12.4%) to a greater extent in
he pioglitazone group relative to placebo.
afety and tolerability. Details of serious adverse events in
he total PROactive population are given in the paper by
ormandy et al. (26). As with the total PROactive study
opulation, there were fewer patients with serious adverse
vents in the pioglitazone group versus the placebo group
580 [47.2%] vs. 620 [51.0%]) in the patients with type 2
iabetes and previous MI.
Heart failure (HF) occurred in a greater proportion of
atients in the MI subgroup (11.6%) than in those without
revious MI (7.0%; p 0.0001). The HR for any HF event
Figure 2 Time to Nonfatal MI (Excluding Silent MI), Coronary R
Acute Coronary Syndrome, or Cardiac Death (Compos
Kaplan-Meier curve of the time to nonfatal MI (excluding silent MI), coronary revas
death (composite cardiac end point). The solid line represents the pioglitazone gron the previous-MI subgroup versus those who did not have iprevious MI was 1.68 (p  0.0001). A similar significant
ifference was noted for the category of HF requiring
ospitalization (HR  1.75; p  0.0001). Fatal HF
ccurred in 28 patients (1.1%) in the previous-MI subgroup
nd 19 (0.7%) in the no-previous-MI subgroup (HR 
.66; p  0.089). In those with a previous MI, there was an
ncrease in serious HF (requiring hospitalization) in the
ioglitazone group (Table 7); however, there was no statis-
ically significant difference in fatal HF (1.4% in the
ioglitazone group vs. 0.9% in the placebo group).
Median alanine aminotransferase decreased in the piogli-
azone group from 25 IU/l at baseline to 24 IU/l (4.2%) at
he final visit, whereas there was an increase from 25 to 27
U/l (8.3%) in the placebo group (p  0.0001 between
roups).
iscussion
ROactive was the first prospective, double-blind outcome
tudy to look specifically at the effects of a glucose-lowering
gent, pioglitazone, on the secondary prevention of macro-
ascular disease in patients with type 2 diabetes. The
atients included in this subanalysis of the study all had
revious MI and thus were at a very high risk for a
ubsequent macrovascular event. The results indicate that
ioglitazone reduces the risk of adverse cardiac outcomes,
cularization,
ardiac End Point)
ation, acute coronary syndrome, or cardiac
e dashed line represents the placebo group. Abbreviations as in Figure 1.evas
ite C
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equires a multifactorial approach to delay or prevent
rogression of macrovascular disease. Antiplatelet agents,
CE inhibitors, beta-blockers, and lipid-altering agents
ave all been shown to decrease long-term mortality and
ardiovascular morbidity in patients with coronary artery
isease. However, prevention of these outcomes with
lucose-lowering agents in patients with type 2 diabetes has
ot been demonstrated in large-scale studies (with the
xception of a significant improvement in macrovascular
vents in a small subgroup analysis of 342 newly diagnosed
bese patients with diabetes treated with metformin in the
KPDS) (29).
The effect of pioglitazone was investigated because, in
ddition to lowering blood glucose, it has a number of
ardiovascular effects that are considered to be beneficial in
therosclerotic disease. Of special interest are pioglitazone’s
Multivariate Analysis Showing the Hazard RatioCharacteristics* (Only Showing Those With a p2 Diabetes and Previous MI
Table 6
Multivariate Analysis Showing the H
Characteristics* (Only Showing Tho
2 Diabetes and Previous MI
n  2,398†
Fatal/
LDL4 mmol/l (vs.3 mmol/l)
Insulin use
Age (yrs)
Previous PCI/CABG
Pioglitazone
n  2,376†
Composite End Poi
(Nonfatal and Silent MI, Coronary R
LDL4 mmol/l (vs.3 mmol/l)
LDL 3–4 mmol/l (vs.3 mmol/l)
Duration 10 yrs (vs.5 yrs)
ACE inhibitor use
Triglycerides2.2 mmol/l (vs.1.7 mmol/l)
Previous PCI/CABG
Pioglitazone
*Baseline factors included in the analysis were age (years); male gen
duration 5 to 10 years (vs.5 years); past smoker (vs. never); current
metformin  sulfonylureas (vs. none); systolic and diastolic blood pre
mmol/l (vs.1.7 mmol/l); HDL cholesterol, 1 to 1.2 mmol/l (vs.1.2
mmol/l (vs.3 mmol/l); LDL cholesterol 3 to 4 mmol/l (vs. 3 mm
stroke; previous ACS; previous PCI/CABG; coronary artery disease do
arterial obstructive disease; prior photocoagulation therapy; metabo
beta-blocker use; statin use; and diuretic use. †Number of patients w
ACE angiotensin-converting enzyme; CABG coronary artery bypass
lipoprotein; MI myocardial infarction; PCI  percutaneous coronary int
eart Failure in Patients With Type 2 Diabetes With and Without P
Table 7 Heart Failure in Patients With Type 2 Diabetes With an
Previous MI,
Number of Events (%)
Ti
End Points
Pioglitazone
(n  1,230)
Placebo
(n  1,215) H
Any report of heart failure 166 (13.5%) 117 (9.6%) 1
Heart failure leading to hospitalization 92 (7.5%) 63 (5.2%) 1
Fatal heart failure 17 (1.4%) 11 (0.9%) 1Pioglitazone versus placebo.
HR  hazard ratio; other abbreviations as in Table 6.ffects on lipid levels (increasing HDL cholesterol, lowering
riglycerides, and beneficially changing the composition of
DL particles) and blood pressure and its regulation of
evels of mediators involved in inflammation and endothelial
ysfunction (e.g., C-reactive protein) (16–22,26,30). In
act, it has been shown (31,32) that one of the widely
ccepted indicators of coronary atherosclerosis and risk of
ardiovascular events, intima-media thickness of the carotid
rtery, is decreased by pioglitazone. Therefore, there was
ood reason to consider the use of pioglitazone in patients
ith macrovascular disease and diabetes. The main results
f the PROactive study showed a significant RR of the
isease-related end points of all-cause mortality, nonfatal
I, and nonfatal stroke in these patients (26). Here, we
onfirm through a subgroup analysis that intervention
ith pioglitazone is also beneficial in especially high-risk
atients.
ciated With Relevant Baseline<0.05) in Pati nts With Type
d Ratio Associated With Relevant Baseline
ith a p Value <0.05) in Patients With Type
Ratio 95% CI p Value
al MI
04 (1.346–3.093) 0.0008
59 (1.147–2.193) 0.0053
03 (1.010–1.056) 0.0050
56 (0.392–0.810) 0.0019
72 (0.521–0.998) 0.0488
Ratio 95% CI p Value
ll Cardiac Events
ularization, ACS, or Cardiac Death)
67 (1.265–2.209) 0.0003
50 (1.202–1.875) 0.0003
44 (1.129–1.836) 0.0033
31 (1.044–1.648) 0.0199
30 (1.036–1.625) 0.0234
68 (0.537–0.871) 0.0020
85 (0.694–1.031) 0.0973
dy mass index; diabetes duration 10 years (vs.5 years); diabetes
r (vs. never); metformin only (vs. none); sulfonylureas only (vs. none);
triglycerides 1.7 to 2.2 mmol/l (vs.1.7 mmol/l); triglycerides2.2
l); HDL cholesterol1 mmol/l (vs.1.2 mmol/l); LDL cholesterol4
bA1c 7.5%; creatinine 130 mol/l; positive micral test; previous
ted by exercise stress test, angiography, or scintigraphy; peripheral
drome; insulin use; ACE inhibitor or angiotensin II antagonist use;
available for a complete analysis.
 confidence interval; HDL high-density lipoprotein; LDL low-density
n.
us MI
ithout Previous MI
Heart Failure*
No Previous MI,
Number of Events (%)
Time to Heart Failure*
% CI; p Value
Pioglitazone
(n  1,375)
Placebo
(n  1,418) HR; 95% CI; p Value
13–1.81; 0.003 115 (8.4%) 81 (5.7%) 1.48; 1.12–1.97; 0.006
06–2.00; 0.022 57 (4.1%) 45 (3.2%) 1.31; 0.89–1.94; 0.171
71–3.24; 0.283 8 (0.6%) 11 (0.8%) 0.75; 0.30–1.86; 0.532AssoValue
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Nonfat
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1.
1.
0.
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May 1, 2007:1772–80 Pioglitazone’s Effects in T2DM and Previous MIey findings. The addition of pioglitazone to existing
edication for management of hyperglycemia, dyslipide-
ia, and hypertension reduced the risk of the end point of
recurrent fatal/nonfatal MI in patients with type 2 diabetes
nd MI by 28% (p  0.045). The Kaplan-Meier estimates
f event rates were 5.3% in the pioglitazone group and 7.2%
n the placebo group at 3 years. There was also a significant
enefit in preventing ACS in these high-risk patients
reated with pioglitazone (37% reduction in risk; p 
.035). In addition, we looked at a composite cardiac end
oint (nonfatal MI, coronary revascularization, ACS, and
ardiac death) and found that there was a statistically
ignificant 19% decrease in risk (p 0.034). All of the other
nd points trended similarly, but did not reach the conven-
ional level of 0.05 for statistical significance.
Although pioglitazone treatment also resulted in im-
rovements in HDL cholesterol and triglycerides, the spe-
ific mediators of pioglitazone’s benefit with regard to
ardiac outcomes are unknown, and this study was not
esigned to determine the mechanisms of cardioprotection.
This particular high-risk subgroup with a MI at the entry
nto the study would be prone to develop HF as a conse-
uence. There was an increase in reports of serious HF
eading to hospitalization (7.5% vs. 5.2%) in the pioglita-
one group, but the rate of fatal HF was similar in the 2
roups (1.4% with pioglitazone vs. 0.9% with placebo). A
ecent analysis of more than 23,000 patients does not
upport the view that pioglitazone may cause HF (33). The
igher relative HF risk shown in the pioglitazone group in
ROactive does not appear to be related specifically to the
rior myocardial function impairment present in the
revious-MI subgroup. The proportion of reports of any
F and serious HF in this MI subgroup were higher than
hose in the no-previous-MI subgroup, regardless of treat-
ent group. There were increased risks of 68% for any HF
vent and 75% for HF leading to hospitalization in the
revious-MI subgroup relative to the no-previous-MI sub-
roup (both p  0.0001).
tudy limitations. The main limitation of this analysis is
hat it includes both prespecified and post-hoc end points. It
s an analysis of a subgroup of a larger study, and random-
zation was not stratified by history of MI. Nevertheless, the
ample size is substantial, and the 2 treatment groups within
his subgroup were very well balanced at baseline. Further-
ore, these data represent one of the largest groups of
atients with type 2 diabetes and previous MI randomized
s part of a diabetes outcome trial.
Although the protocol specified that investigators follow
he IDF Europe guidelines and the executive committee
einforced that, not all of the patients were treated accord-
ngly. For example, according to the guidelines, all of the
atients should have been receiving a statin. At baseline,
pproximately 50% of patients received a statin. By 3 years
his had risen to 63%. Recent surveys also show that, in
urrent practice, there is an underuse of statins in people
ith cardiovascular disease and/or diabetes, with 22% to5% usage in European countries (34–38). However, the
eneficial effect of pioglitazone in this previous-MI sub-
roup was independent of baseline use of a statin based on
multivariate analysis.
The time period of the study was relatively short, con-
idering the chronic nature of treatment. The benefit of
ioglitazone is clear from the Kaplan-Meier curves for both
ime to fatal/nonfatal MI and time to the composite cardiac
nd point. If the study duration had been longer, continued
ivergence of the curves (if it occurred) would have
trengthened our findings.
onclusions. In this analysis of a subgroup of high-risk
atients with type 2 diabetes and a previous MI from a large
rospective study, pioglitazone appears to be effective in
educing the risk of recurrent MI and other serious cardio-
ascular events.
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